NASDAQ:NVAX
Novavax Inc.
Novavax Inc.'s revenue grew 64.7% in fiscal 2025 to $1.1B while operating margin rose to 40.3%, its highest in 10 years. The diluted share count rose 13.7%.Summary generated from Novavax Inc.'s SEC filings. Latest annual report filed Feb 26, 2026.
Key statistics
Fiscal 2025 from SEC filings. MethodologyRevenue (FY25)$1.1B
Revenue growth+64.7%
Revenue, 5-yr CAGR+18.8%
Gross margin93.5%
Operating margin40.3%
Net margin39.2%
ROICn/a
Return on equityn/a
Debt / equityn/a
Free cash flown/a
FCF marginn/a
Share count change+13.7%
Financials
| Item | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Revenue | 1,146 | 1,982 | 984 | 682 | 1,123 |
| Operating income | −1,687 | −645 | −567 | −249 | 453 |
| Net income | −1,744 | −658 | −545 | −187 | 440 |
| Free cash flow | 265 | n/a | n/a | n/a | n/a |
Recent filings
- 8-KResults of operations and financial condition
Aug 6, 2026 - 10-QQuarterly report for the period ended Jun 30, 2026
Aug 6, 2026 - 4Insider transaction report
Jun 23, 2026 - 4Insider transaction report
Jun 23, 2026 - 8-KResults of a shareholder vote
Jun 23, 2026 - 8-KResults of operations and financial condition
May 6, 2026 - 10-QQuarterly report for the period ended Mar 31, 2026
May 6, 2026 - DEF 14AProxy statement
Apr 27, 2026